in

Serum Institute looking at bilateral deals to supply Covishield vaccine

As India outshines China with its friendly neighbourhood vaccine diplomacy, the world’s largest vaccine maker — Serum Institute of India (SII) — is girding itself for bilateral deals to supply to low- and medium-income countries. The Pune-based biotechnology company will increase capacity to manufacture the Oxford-AstraZeneca-developed Covishield vaccine by 30 per cent by March, from the current daily levels of 2.4 million doses.

The firm has entered into a deal with Bangladesh. The neighbouring nation has so far purchased 30 million doses from SII through a private …



Reference